"As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers. 07 MARCH 2023. Following Sanofi's January announcement that it will pay $11.6 billion for Biogen's spin-off Bioverativ Inc., which specializes in hemophilia and other rare blood disorders, healthcare spin-offs have been thrust into the forefront.. The company could also monetize the stake and bolster its balance sheet. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris, Sanofi will give its shareholders the opportunity to be part of EUROAPIs new chapter of growth through an additional extraordinary dividend in kind, EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions, The French State, through the fund French Tech Souverainet, intends to acquire 12% of EUROAPIs capital for up to 150 million from Sanofi to become a long-term reference shareholder of EUROAPI, As planned, Sanofi will continue to hold circa 30% of EUROAPI, post transaction, The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPIs French prospectus. In November 2021, Johnson & Johnson announced it would also split off its consumer . Neither Sanofi nor EUROAPI assumes any responsibility for any violation of any such restrictions by any person. The Consumer Healthcare unit had two major deals in 2018, when GSK acquired Novartis' 36.5% stake in its consumer healthcare joint venture (JV) followed by a merger with Pfizer's consumer healthcare business into a JV. You may opt-out by. Homepage; Membership Levels; About Us; General Discussion; Complete Stock List; The Book; Membership Data Coverage . As part of Sanofi's ongoing efforts to reduce the complexity of its Consumer Healthcare portfolio and accelerate its growth trajectory, the company has signed an agreement with STADA for the divestiture of 16 Consumer Healthcare products commercialized in Europe. Our mission is to Serve Healthier, Fuller Lives by offering moments of relief to our Patients & Consumers in our key platforms, including Allergy, Physical & Mental Wellness, Pain . Paris, March 18 2022. Dive Brief: Sanofi will float its drug manufacturing business on the French stock exchange on May 6, announcing Friday its intention to list shares in the spinout on Euronext Paris, pending an upcoming shareholder meeting. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. Grow with us; Diversity & Inclusion; Development opportunity: how Sanofi empowers you; Opinions expressed by Forbes Contributors are their own. We believe the deteriorating performance at the largest segment may have triggered the need to refocus on the biopharma business. We recognize that allergies can be challenging and symptoms such as itchy eyes, sneezing and a runny nose can be a burden to getting on with everyday life. Therefore, their poor performance affects the overall results: General Medicines declined by 9% and Consumer Healthcare by 14% YoY. Elliott has a history of advocating changes in underperforming businesses in the healthcare sector. Career opportunities. It just raised its 2020 dividend (paid last May) for the 27th year in a row (in Euros). Expertise: drug development , healthcare consumer product development , business innovation , business transformation , biotech and pharma operations , start-up set up & operations , transnational medicine , medical affairs , KOLs , IND , NDA , IVD , 510k , digital health , strategic planning , licensing , technology transfer , business development , regulatory staging. She is particularly interested in stories about AI, antibiotic resistance, and global health equality. With Bill Sibold, EVP, Specialty Care & Frank Nestle, Global Head of Research, Chief Scientific Officer Last month, GSK - which owns a larger portion of the companies' shared consumer division - said it was "on track" to spin off the business, with a representative adding the split could take place as soon as mid-2022. How management will address them we dont know of course, but here are some likely solutions they may put in place in a relative short time which will act as strong catalysts for Sanofis business. GSK claimed strengthened governance through the appointments of former Bristol-Myers Squibb executive Charles Bancroft and Anne Beal as non-executive directors. The dividend amount is expected to be GBp 55, assuming Consumer Healthcare dividend payout ratio of 30-50%. Start Now! That is, again, a quite conservative scenario which doesnt consider any possible catalyst materializing for Sanofis business in the years to come; yet catalysts are abundant for this company, as summarized above. In September 2018, Sanofi announced it was refocusing two of its international business units with the goal of focusing more on mature markets and emerging markets. The approach mirrors Novartis' own move to carve out its Sandoz generics unit which private equity groups like EQT AB (publ), Blackstone Inc. and The Carlyle Group Inc. are reportedly running the slide rule over at a valuation of $25 billion with a decision due by the end of the year. The CEO's review of the consumer unit coincided with a trend for pharmaceutical giants like Johnson & Johnson and GlaxoSmithKline PLC to simplify their diversified structures and double-down on lucrative franchises, such as cancer and rare disease, driven by pioneering science, data and technological advances. Sanofi does not anticipate any impact of this divestiture to its European-based workforce. It already has a first pocket of 150M to support French technology companies developing future technologies of a sovereign nature, which may fall prey to large foreign players or be overtaken by competitors who are able to finance themselves better. Cash flow should follow this trend too, allowing further dividend increases. We are pleased these products will continue to be available for consumers as we focus on becoming a fully integrated standalone business said Julie Van Ongevalle, Executive Vice-President, Sanofi and Head of Sanofi Consumer Healthcare. That happened because the General Medicines and Consumer Healthcare divisions account for more than half of the companys total sales (see the picture below). The company operates in three major business segments, Pharmaceuticals, Vaccines and Consumer Healthcare. About Sanofi Sanofi assumes no responsibility for the information presented on this website. Welcome to Sanofi Consumer Healthcare. The rationale is that the company, whose innovation engine has been strongly reliant on its relationship with Regeneron Pharmaceuticals, would be able to invest the proceeds into more internal research. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, https://www.sanofi.com/en/investors/contact. At its third-quarter financial report on October 31, Sanofi reported total net sales of 9.499 billion for the quarter, with Consumer Healthcare reporting 1.136 billion, up 0.4%. Josephine Fubara With a diversified technology portfolio, EUROAPI is positioned as the world's leading manufacturer of small molecule API (including complex chemical synthesis molecules, biochemical molecules from fermentation and highly potent molecules). Take a look at highlights from our portfolio of self-care products. Detail: Visit URL Category: Business View Health There are certain watershed moments in every person's life that propel them to find a community. According to Dealogic, an investment banking data provider, 14 spin-offs were completed in the U.S. last year, of which two were healthcare: Bioverativ and . Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's 135-year history. Anyway, it is not nave to think that, at the moment, this company has a few problems that must be addressed. The separation is expected to complete by mid-2022E. Across the world, 77% of people have used nutritionals in the last 12 months to maintain their general health, provide immune system support or to supplement in areas of vitamin deficiency. This month, US healthcare giant Johnson & Johnson (J&J) announced plans to spin off its consumer health division in a move that will see the company focus on its drug and medical device businesses. Sandrine Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com . Prioritization will become increasingly important going forward, Hudson told reporters. Sanofi said on Tuesday it hopes to take over the consumer health care unit of German peer Boehringer Ingelheim via an asset swap, making the French pharmaceutical giant the sector's world leader. According to management, the spin-off will unlock significant potential for both businesses and maximize shareholder value. Although Sanofis management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Johnson & Johnson, Bayer and Sanofi, according to Reuters, are close competitors in the consumer healthcare market. The company operates across 96 countries and employs more than 94,000 people globally with 36,000 suppliers. Roche. As a part of deal, GSK held majority controlling equity interest of 68% in the JV and the rest 32% equity interest was owned by Pfizer. Please. All in all, considering both the current stock price and the possible catalysts to unlock the intrinsic value of the company, Sanofi is a buy. I have developed a broad set . 1 Companys estimate based on third-party market research conducted using the annual reports published by the main industrial players in the APIs sector, public databases (including Capital IQ and Orbis) as well as interviews with market experts. Post separation, the stub unit will operate as a biopharma company concentrated on specialty medicines and vaccines, while the spin-off unit will focus on category-leading power brands. *About Active Pharmaceutical Ingredients (APIs) The new head of the division, Julie Van Ongevalle, shared that the company will focus on core brands and categories while pursuing first-in-class Rx-to-OTC switches in the ED and flu categories in the U nited States. On the other hand, the remaining part is progressing nicely. We are committed to providing world-class products and services that help manage energy, stress, sleep and anxiety. However, the French dividend tax for foreign individuals amounts to just 12.8%. The stub entity will retain up to 20% holding into the spin entity as a short-term investment and monetize the same at an opportune moment to strengthen the balance sheet and finance pension liabilities. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Active Pharmaceutical Ingredients (APIs) are the chemical or biological substances in a medicine that have a therapeutic effect. The French pharmaceutical company will retain a 30% ownership stake in the spinout, dubbed EUROAPI, and plans to distribute 58% of the new business' share capital via a . Landmark New England Journal of Medicine publication reinforces potential of GSK's respiratory syncytial virus older adult vaccine candidate. EUROAPI develops, manufactures, markets and distributes APIs and intermediates used in the formulation of medicines for human and veterinary use, both from originators and generics, through its API Solutions business and CDMO activities. The one-shot cervical cancer vaccine paradigm. Sanofi CEO's strategy blueprint may include consumer health spinoff or merger: Bloomberg | Fierce Pharma . Moreover, the failure to come out with a COVID-19 vaccine despite being one of the largest vaccine producers, may have led to investor disappointment. I am not receiving compensation for it (other than from Seeking Alpha). -. Real-time Euronext Paris It followed a historic slump in over-the-counter sales for cough and cold medicines across the industry in 2020 as a result of social distancing and other pandemic-related regulations. Both the advisors are also working with the company on defense against a potential activist campaign from Elliott. Today marks a major milestone for EUROAPI, a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients* (API), as Sanofis Board of Directors unanimously proposed, on March 17th, to submit to its shareholders the distribution of circa 58% of the share capital of EUROAPI. Partnered with business leaders to facilitate the Retired after 24+ year career with J&J. Colds are one of the most common illnesses experienced by both adults and children. In the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually.2. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . The Consumer Healthcare business comprises major brands targeting oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements. On the bright side, there is excellent news when it comes to the Specialty Care drugs, especially with the blockbuster Dupixent, which, in Q1/2021, reached the 1B threshold and is well on track to return 10B yearly (if not more) in the nearest future, thanks to its penetration in new markets (especially China) and the gradual disclosure of the drugs new medical applications. While GlaxoSmithKline boasts a higher dividend yield at 5.4% than Sanofi's 3.6%, Sanofi . The company expects to announce a strategic plan in December. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Scotland Health Tech privacy policy. Get Your 7-Day Free Trial! Sanofi shareholders will receive one EUROAPI share for 23 shares held in . At that time, Sanofi's three remaining global business units, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare weren't changing. About STADA Arzneimittel AG The patent stays until 2035 to 2039 (oral form). Again, the sooner the better. However, it looks like that les grandes manoeuvres, aimed at the realization of this project, will proceed at a slow speed. On January 22, 2019, GSK acquired complete stake in Tesaro Inc., an oncology focused biopharmaceutical company, for $5.0 billion (3.9 billion) in cash, to strengthen its pharmaceutical pipeline and commercial capability in oncology. Please disable your ad-blocker and refresh. Precision medicine and digital health innovation for disease diagnosis, care and treatment, Enabling process intensification in biopharma manufacturing, Specialty drug launch strategy and operations, The next chapter of clinical trial services, Putting quality first in the pharma supply chain, Enabling better biopharmaceutical manufacturing, Pharmaceutical Grade Silicone Manufacturer, Venture financing for APAC early-stage innovator drugs raises one-third less than US, Beyond Covid-19: the disruptive potential of RNA-based therapeutics, IN-10018 by InxMed (Beijing) for Epithelial Ovarian Cancer: Likelihood of Approval, Sunshine Biopharma signs licence deal for Covid-19 treatment, Orions darolutamide receives Japans MHLW approval for prostate cancer, CHMP recommends against Merck-Ridgebacks Covid-19 medicine authorisation, Environmental sustainability innovation: Leading companies in lactobacilli-based probiotics, AbbVie reports rise in full-year 2022 net revenues, Teva Pharmaceutical reports 5% fall in Q4 2022 revenue, Merckreports 2% increase in worldwide sales in Q4 2022, Resolving challenges with product recovery in biopharma manufacturing, Rare Disease Day: Why raising awareness is essential for a fairer future, The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development. Market Intelligence Bronchiolitis Obliterans Drugs in Development by Stages, Tar Thailand Healthcare (Pharma and Medical Devices) Market Anal Malaysia - Healthcare (Pharma and Medical Devices) Market An Israel Healthcare (Pharma and Medical Devices) Market Analys Colombia Healthcare (Pharma and Medical Devices) Market Anal Magazine: Right shoring API production in Europe, CMO Moves: Regulatory catalysts for drug manufacturing- February. Forward-looking statements are statements that are not historical facts. "If the GlaxoSmithKline Consumer Health spinoff goes well, we believe it is likely that Sanofi could spin off its consumer health business as well, which is a reasonable extension of the internal separation that is ongoing," HSBC analyst Steve McGarry said in a Nov. 1 note. Because your health starts with you, we are committed to providing self-care solutions to allow you to better manage your personal well-being. Business is on track to demerge and list as a new company in mid-2022. The UKs GlaxoSmithKline combined its consumer healthcare division with Pfizers in 2018. Published: Nov 21, 2019 The company intends to structure the transaction in a tax efficient manner for both the UK and US shareholders, subject to confirmation from the relevant tax authorities. The move has been in the works for several months. French Tech Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other customary conditions. In addition to the previously proposed 3.33 cash dividend per Sanofi share, this additional extraordinary dividend, exclusively in kind, is subject to shareholders approval at Sanofi's May 3, 2022 Ordinary and Extraordinary Shareholders' Meeting. Cowen's 43rd Annual Health Care Conference With Bill Sibold, EVP, Specialty Care & Frank Nestle, Global Head of Research, Chief Scientific Officer > Add the event to my calendar
Creflo Dollar Plane Crash,
Cruisin' The Coast 2022 Registration,
St Francois County Mugshots,
Urogenital Flora At 3 Days,
Costa Del Mar Rubber Replacement,
Articles S